Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties ...

Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

Novavax faces significant financial challenges, with high leverage and declining revenue growth. While strategic partnerships and asset restructuring provide some optimism, the overall outlook remains ...

Vaccines have been globally regarded as the pillar of infectious disease control and prevention. From development to their approval can take several years. Now, the FDA, the U.S. regulator overseeing ...

Moderna MRNA announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the EU approval of mNexspike ...